Trial · NCT03549871
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Factor/BPA Prophylaxis: Day -168 to -1 | STARTED | Cohort A: Inhibitor | 30 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | STARTED | Cohort B: Non-inhibitor | 50 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | Started Directly With Fitusiran | Cohort A: Inhibitor | 2 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | Started Directly With Fitusiran | Cohort B: Non-inhibitor | 0 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | Started With Factor or BPA Prophylaxis | Cohort A: Inhibitor | 28 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | Started With Factor or BPA Prophylaxis | Cohort B: Non-inhibitor | 50 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | COMPLETED | Cohort A: Inhibitor | 23 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | COMPLETED | Cohort B: Non-inhibitor | 46 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | NOT COMPLETED | Cohort A: Inhibitor | 7 | |
| Factor/BPA Prophylaxis: Day -168 to -1 | NOT COMPLETED | Cohort B: Non-inhibitor | 4 | |
| Fitusiran Treatment: Day 1 to Day 190 | STARTED | Cohort A: Inhibitor | 23 | |
| Fitusiran Treatment: Day 1 to Day 190 | STARTED | Cohort B: Non-inhibitor | 46 | |
| Fitusiran Treatment: Day 1 to Day 190 | Received 80mg QM & Part of Safety Analysis Set 1 (SAS 1) | Cohort A: Inhibitor | 21 | |
| Fitusiran Treatment: Day 1 to Day 190 | Received 80mg QM & Part of Safety Analysis Set 1 (SAS 1) | Cohort B: Non-inhibitor | 46 | |
| Fitusiran Treatment: Day 1 to Day 190 | Received 50 mg Q2M & Part of Safety Analysis Set 2 (SAS 2) | Cohort A: Inhibitor | 2 | |
| Fitusiran Treatment: Day 1 to Day 190 | Received 50 mg Q2M & Part of Safety Analysis Set 2 (SAS 2) | Cohort B: Non-inhibitor | 0 | |
| Fitusiran Treatment: Day 1 to Day 190 | Efficacy Analysis Set 1 (EAS 1) | Cohort A: Inhibitor | 19 | |
| Fitusiran Treatment: Day 1 to Day 190 | Efficacy Analysis Set 1 (EAS 1) | Cohort B: Non-inhibitor | 46 | |
| Fitusiran Treatment: Day 1 to Day 190 | Efficacy Analysis Set 2 (EAS 2) | Cohort A: Inhibitor | 2 | |
| Fitusiran Treatment: Day 1 to Day 190 | Efficacy Analysis Set 2 (EAS 2) | Cohort B: Non-inhibitor | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03549871/flow